Sarepta shares soar as gene therapy study shows promise
(Reuters) - Sarepta Therapeutics Inc shares jumped 60 percent on Tuesday after the drugmaker reported promising results from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Gene Therapy | Genetics | Health | Muscular Dystrophy | Reflex Sympathetic Dystrophy | Study